Krystal Biotech Inc (KRYS)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| CEO: | Krish S. Krishnan |
| Employees: | 210 |
| Web site: | krystalbio.com |
|
2100 WHARTON STREET, SUITE 701, PITTSBURGH, PA, 15203
(412) 586-5830
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Krystal Biotech, Inc. engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105, KB301, KB407, KB104, KB5xx and KB3xx product.
Please log in first to see chart